ZLN005 - CAS 49671-76-3
Catalog number: 49671-76-3
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H18N2
Molecular Weight:
250.34
COA:
Inquire
Targets:
PGC-1α
Description:
Selective transcriptional regulator of peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α). ZLN005 selectively stimulated the expression of PGC-1α and downstream genes in skeletal muscle cells, and led to changes in glucose uptake, and fatty acid oxidation in L6 myotubes in a AMPK dependent manner. Since ZLN 005 did not increase the expression of the PGC-1α gene in rat primary hepatocytes, it is hypothesized that expression of PGC-1α was regulated in a cell type–specific manner. ZLN005 exerts promising therapeutic effects for treating type 2 diabetes, as PGC-1α is a powerful transcriptional coregulator of GLUT4 and mitochondrial genes, a crucial player in the field of glucose uptake in skeletal muscle.
Purity:
>98%
Synonyms:
ZLN005; ZLN-005; ZLN 005.
MSDS:
Inquire
InChIKey:
LQUNNCQSFFKSSK-UHFFFAOYSA-N
InChI:
InChI=1S/C17H18N2/c1-17(2,3)13-10-8-12(9-11-13)16-18-14-6-4-5-7-15(14)19-16/h4-11H,1-3H3,(H,18,19)
Canonical SMILES:
CC(C)(C)C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2
1.In vitro and in vivo metabolite identification of a novel benzimidazole compound ZLN005 by LC-MS/MS.
Sun W;Nguyen KD;Fitch WL;Banister SD;Tang H;Zhang X;Yu L;Engleman EG;Rajadas J Rapid Commun Mass Spectrom. 2018 Jan 15. doi: 10.1002/rcm.8060. [Epub ahead of print]
RATIONALE: ;A novel benzimidazole compound ZLN005 was previously identified as a transcriptional activator of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) in certain metabolic tissues. Upregulation of PGC-1α by ZLN005 has been shown to have beneficial effect in a diabetic mouse model and in a coronary artery disease model in vitro. ZLN005 could also have therapeutic potential in neurodegenerative diseases involving down-regulation of PGC-1α. Given the phenotypic efficacy of ZLN005 in several animal models of human disease, its metabolic profile was investigated to guide the development of novel therapeutics using ZLN005 as the lead compound.;METHODS: ;ZLN005 was incubated with both rat and human liver microsomes and S9 fractions to identify in vitro metabolites. Urine from rats dosed with ZLN005 was used to identify in vivo metabolites. Extracted metabolites were analyzed by LC-MS/MS using a hybrid linear ion trap triple quadrupole mass spectrometer under full scan, enhanced product ion scan, neutral loss scan and precursor scan modes. Metabolites in plasma and brain of ZLN005-treated rats were also profiled using multiple reaction monitoring.;RESULTS: ;Identified in vitro transformations of ZLN005 include mono- and dihydroxylation, further oxidation to carboxylic acids, and mono-O-glucuronide and sulfate conjugation to hydroxy ZLN005 as well as glutathione conjugation.
2.The PGC-1α Activator ZLN005 Ameliorates Ischemia-Induced Neuronal Injury In Vitro and In Vivo.
Xu Y;Kabba JA;Ruan W;Wang Y;Zhao S;Song X;Zhang L;Li J;Pang T Cell Mol Neurobiol. 2018 May;38(4):929-939. doi: 10.1007/s10571-017-0567-0. Epub 2017 Nov 20.
Oxidative stress is a great challenge to neurons following cerebral ischemia. PGC-1α has been shown to act as a potent modulator of oxidative metabolism. In this study, the effects of ZLN005, a small molecule that activate PGC-1α, against oxygen-glucose deprivation (OGD)- or ischemia-induced neuronal injury in vitro and in vivo were investigated. Transient middle cerebral artery occlusion (tMCAO) was performed in rats and ZLN005 was administered intravenously at 2 h, 4 h, or 6 h after ischemia onset. Infarct volume and neurological deficit score were detected to evaluate the neuroprotective effects of ZLN005. Well-differentiated PC12 cells, which were subjected to OGD for 2 h followed by reoxygenation for 22 h, were used as an in vitro ischemic model. Changes in expression of PGC-1α, its related genes, and antioxidant genes were determined by real-time quantitative PCR. The results showed that ZLN005 reduced cerebral infarct volume and improved the neurological deficit in rat with tMCAO, and significantly protected OGD-induced neuronal injury in PC12 cells. Furthermore, ZLN005 enhanced expression of PGC-1α in PC12 cells and in the ipsilateral hemisphere of rats with tMCAO. Additionally, ZLN005 increased antioxidant genes, including SOD1 and HO-1, and significantly prevented the ischemia-induced decrease in SOD activity.
3.PGC-1α (Peroxisome Proliferator-Activated Receptor γ Coactivator 1-α) Overexpression in Coronary Artery Disease Recruits NO and Hydrogen Peroxide During Flow-Mediated Dilation and Protects Against Increased Intraluminal Pressure.
Kadlec AO;Chabowski DS;Ait-Aissa K;Hockenberry JC;Otterson MF;Durand MJ;Freed JK;Beyer AM;Gutterman DD Hypertension. 2017 Jul;70(1):166-173. doi: 10.1161/HYPERTENSIONAHA.117.09289. Epub 2017 May 22.
Blood flow through healthy human vessels releases NO to produce vasodilation, whereas in patients with coronary artery disease (CAD), the mediator of dilation transitions to mitochondria-derived hydrogen peroxide (;mt;H;2;O;2;). Excessive ;mt;H;2;O;2; production contributes to a proatherosclerotic vascular milieu. Loss of PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) is implicated in the pathogenesis of CAD. We hypothesized that PGC-1α suppresses ;mt;H;2;O;2; production to reestablish NO-mediated dilation in isolated vessels from patients with CAD. Isolated human adipose arterioles were cannulated, and changes in lumen diameter in response to graded increases in flow were recorded in the presence of PEG (polyethylene glycol)-catalase (H;2;O;2; scavenger) or L-NAME (;N;G;-nitro-l-arginine methyl ester; NOS inhibitor). In contrast to the exclusively NO- or H;2;O;2;-mediated dilation seen in either non-CAD or CAD conditions, respectively, flow-mediated dilation in CAD vessels was sensitive to both L-NAME and PEG-catalase after PGC-1α upregulation using ZLN005 and α-lipoic acid. PGC-1α overexpression in CAD vessels protected against the vascular dysfunction induced by an acute increase in intraluminal pressure.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PGC-1α Products


CAS 49671-76-3 ZLN005

ZLN005
(CAS: 49671-76-3)

Selective transcriptional regulator of peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α). ZLN005 selectively stimulated the expression of PGC...

Chemical Structure

CAS 49671-76-3 ZLN005

Quick Inquiry

Verification code

Featured Items